ARTICLE | Clinical News
D-JNKI-1: Phase III started
June 27, 2016 7:00 AM UTC
Auris began the double-blind, placebo-controlled, international Phase III ASSENT trial to evaluate single doses of 0.4 and 0.8 mg/mL intratympanic AM-111 plus background therapy with oral corticostero...